Targeted Therapies and Eruptive Skin Growths: Key Numbers Breakdown
Targeted oncology therapies have transformed treatment strategies for complex malignancies, yet their influence on cellular signaling pathways can produce rapid, unexpected dermatological events. When signaling cascades in the skin are altered, patients may observe sudden shifts in cutaneous architecture. A notable report published in Cureus details an uncommon clinical presentation where a patient receiving targeted cancer medications developed widespread eruptive moles alongside keratinocyte growths at the same time. Understanding these events provides critical perspective on how systemic signaling pathways regulate skin cells and why professional medical evaluation is crucial whenever unusual growths appear.
1 Subject Investigation: Study Design and Inherent Limitations
The foundation of this research rests on a single-patient medical report published in Cureus (PMID 39479087) in 2024. The publication documents the case of a 64-year-old male undergoing treatment for metastatic colorectal cancer. His therapeutic regimen included encorafenib, an inhibitor targeting v-Raf murine sarcoma viral oncogene homolog B (BRAF), administered concurrently with panitumumab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody.
Because this evidence derives from an isolated case report, significant methodological boundaries apply. Case reports are observational and cannot establish broad population prevalence, absolute incidence rates, or predict individual susceptibility. Instead, they serve as initial signals that identify rare physiological patterns and emphasize the necessity of structured dermatological oversight during targeted therapies.
2 Concurrent Cutaneous Manifestations: Melanocytic and Keratinocyte Proliferation
Following the initiation of encorafenib and panitumumab, the patient developed severe pruritus accompanied by an outbreak of widespread new skin lesions. Dermatological assessment uncovered two distinct categories of growths presenting simultaneously:
- Pigmented Lesions: Eruptive melanocytic nevi, identified as benign clusters of melanocytes.
- Non-Pigmented Lesions: Multiple keratoacanthomas, which represent rapid growths originating from keratinocytes.
While melanocytic proliferations relate to pigment cells, keratoacanthomas involve epidermal keratinocytes. While monitoring continued, larger keratoacanthomas failed to resolve on their own, requiring surgical excision. Subsequent microscopic evaluation of the excised tissue confirmed lichenoid keratosis. Individuals tracking pigment developments or unusual lesions can explore how practitioners assess atypical spots through melanotan, moles and melanoma case reports to understand the importance of formal biopsy over self-diagnosis.
Score of 9: Quantifying Drug Causality on the Naranjo Scale
To determine whether the skin reactions were truly linked to encorafenib rather than incidental changes, clinicians utilized the Naranjo adverse drug reaction probability scale. The assessment yielded an overall score of nine.
On the standardized Naranjo framework, a score of nine establishes a definite association between the therapeutic agent and the adverse cutaneous reaction. This analytical measure helped the medical team conclude that encorafenib was the primary driver behind both the eruptive benign nevi and the multiple keratoacanthomas.
1 Biological Pathway: The Role of Paradoxical MAPK Activation
The clinical researchers explored the biological mechanics behind these reactions, focusing on the mitogen-activated protein kinase pathway. While BRAF inhibitors like encorafenib are designed to suppress aberrant signaling in tumor cells carrying specific mutations, they can sometimes trigger paradoxical activation of the mitogen-activated protein kinase pathway in normal cells.
This paradoxical signaling stimulation in wild-type cutaneous cells provides a working explanation for why both melanocytes (producing eruptive melanocytic nevi) and keratinocytes (forming keratoacanthomas and lichenoid keratosis) proliferated rapidly. Investigating these cellular pathways reinforces that manipulating cellular receptors or hormonal signals can lead to profound, unpredictable skin changes.
Treatment Cessation and Dermatological Management
The course of these eruptive lesions shifted dramatically when the medical team adjusted the oncology regimen. Discontinuation of encorafenib and panitumumab led to the gradual resolution of most skin lesions. This regression after withdrawal further supported the causal relationship between the targeted agents and the cutaneous eruption.
The authors of the Cureus report underscored that comprehensive dermatologic evaluation and routine follow-up are vital for individuals undergoing treatment with BRAF inhibitors. Establishing specialized skin surveillance helps clinicians properly diagnose eruptive benign nevi and keratoacanthomas, manage adverse reactions effectively, and prevent unnecessary or premature cessation of essential cancer therapies. Anyone noticing rapid changes across their skin should rely on tools such as the ABCDE mole check system and seek direct guidance from a dermatologist.
Sources
Published October 28, 2026. Sources are linked in the text. See our Medical Disclaimer.